Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07625332 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)
A Phase 2 study, sponsored by Northwell Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07625332 is a Phase 2 study that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 60 participants.
The verdict
NCT07625332, a Phase 2 study, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this research study is to measure the tolerability and preliminary efficacy of a drug, galantamine, to treat metabolic syndrome (MetS) by reducing circulating inflammation in people with spinal cord injury (SCI). Galantamine is FDA-approved for the treatment of Alzheimer's disease. Here, the drug is considered experimental for the purposes of this study.
Interventions
- DRUG Galantamine Hydrobromide Extended Release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-06-15 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07625332
The ClinicalTrials.gov registry entry for NCT07625332 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Galantamine Hydrobromide Extended Release is the first listed.
NCT07625332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07625332 about?
NCT07625332 is a clinical study titled "Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)". The purpose of this research study is to measure the tolerability and preliminary efficacy of a drug, galantamine, to treat metabolic syndrome (MetS) by reducing circulating inflammation in people with spinal cord injury (SCI). Galantamine is FDA-approved for the treatment of Alzheimer's disease. He...
What is the current status of trial NCT07625332?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-06-15. Estimated completion is 2027-12.
What interventions are being tested in trial NCT07625332?
The interventions under investigation include: Galantamine Hydrobromide Extended Release (DRUG).
Who is sponsoring clinical trial NCT07625332?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.